Cloning of the t(14; 18) chromosomal breakpoint in follicular lymphoma led to the discovery of the bc1-2 proto-oncogene (Tsujimoto et al., 1984; Cleary et al., 1986; Tsujimoto and Croce, 1986) . Gene transfer experiments have demonstrated a role for bcl-2 in preventing apoptosis in growth factordeprived haemopoietic cell lines (Vaux et al., 1988; Nuiiez et al., 1990 ) and in neurotrophic factor-deprived neurons (Garcia et al., 1992; Allsopp et al., 1993) . In transgenic mice bct-2 has been shown to prolong cell survival (McDonnell et al., 1989; Strasser et al., 1990) . Antisense-mediated inhibition of bcl-2 gene expression reduces leukaemic cell growth and survival in an in vitro setting (Reed et al., 1990) . Hockenberry et al. (1990) concluded bcl-2 to be unique among protooncogenes by its ability to block programmed cell death without promoting cell proliferation, which led to its categorisation as a member of a new category of oncogenes: regulators of cell death (Korsmeyer, 1992) .
The 25 kDA bcl-2 protein contains a hydrophobic COOHterminal region allowing post-translational insertion into intracellular membranes and orientation towards the cytosol (Chen-Levy and Cleary, 1990) . Studies on the subcellular location of the bcl-2 protein have demonstrated its residence in the nuclear envelope, parts of the endoplasmic reticulum, the outer mitochondrial membrane and to a lesser extent in the plasma membrane (Krajewski et al., 1993; Akao et al., 1994; de Jong et al., 1994) . Although its exact biochemical mechanism of action remains largely unexplained, an important physiological role for bcl-2 in cell development and differentiation, in tissue homeostasis and in morphogenesis was shown in immunohistochemical studies on fetal and adult human tissues of different origin (Hockenberry et al., 1991; LeBrun et al., 1993; Lu et al., 1993) .
Immunohistochemical studies on bcl-2 expression in human breast cancer have demonstrated a strong association with oestrogen receptor (ER) status, illustrating the possibility that bcl-2 is an ER regulated gene (Bhargava et al., 1994; Chan et al., 1993; Doglioni et al., 1994; Gee et al., 1994; Leek et al., 1994; Nathan et al., 1994; Silvestrini et al., 1994) . The presence of bcl-2 protein immunostaining has been shown to be associated with a low apoptotic index in malignant mammary epithelium (Chan et al., 1993 al., 1994; Doglioni et al., 1994; Joensuu et al., 1994; Silvestrini et al., 1994 ). An inverse correlation was noticed between bcl-2 protein expression and proliferative activity as measured by Ki 67 immunostaining and [3H]thymidine labelling index (Doglioni et al., 1994; Silvestrini et al., 1994) . Furthermore, loss of bcl-2 expression has been associated with presence of a range of molecular markers of poor prognosis in breast cancer, including epidermal growth factor receptor (EGFR), c-erb-B2 and p53 (Doglioni et al., 1994; Gee et al., 1994; Joensuu et al., 1994; Leek et al., 1994; Nathan et al., 1994; Silvestrini et al., 1994) . In a recently published study on bcl-2 expression in axillary nodenegative breast cancer, no prognostic role for bct-2 on 6 year relapse-free and overall survival was retained following multivariate analysis (Silvestrini et al., 1994) . In a series of 174 breast cancers with long-term follow-up, which were primarily treated by surgery with or without locoregional radiotherapy, no prognostic role for bcl-2 expression was observed following multivariate analysis (Joensuu et al., 1994) .
The aim of the present study was to determine immunohistochemically the expression of the bcl-2 proto-oncogene in a series of invasive ductal breast cancers and to evaluate the prognostic value of bcl-2 expression in axillary node-negative and axillary node-positive breast cancer.
Materials and methods
Patients andfollow-up The study group consisted of 251 women who underwent surgery for primary invasive ductal breast carcinoma between March 1979 and June 1992 Bloom and Richardson (1957) . Data on tumour grade, tumour size, nodal status, presence or absence of metastatic disease and menopausal status are given in Table I . Menopausal status was assessed using serum gonadotrophin and oestradiol measurements in perimenopausal patients. Axillary nodenegative patients were followed conservatively and received no adjuvant treatment. Axillary node-positive premenopausal patients had six cycles of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) polychemotherapy. Axillary node-positive post-menopausal patients received adjuvant endocrine treatment (tamoxifen, 20 mg day-' orally). All patients underwent a follow-up physical examination every 6 months and had further investigations if they developed symptoms or signs suggestive of recurrent or metastatic disease. The median follow-up time in our study group was 91 months (range 24-186 months). Ethical committee approval was sought and received for this clinical study.
Immunohistochemistry Formalin-fixed, paraffin-embedded representative primary tumour samples were available for all patients. Five-micronthick sections were cut and mounted onto 3-aminopropyltriethoxysilane-coated glass slides. They were dewaxed in xylene followed by rehydration in decreasing ethanol series, water and phosphate-buffered saline (PBS) pH 7.4. Endogenous peroxidase activity was quenched in 0.3% hydrogen peroxide in 100% methanol, followed by rehydration through graded ethanol and distilled water. Subsequently an antigen retrieval procedure for formalin-fixed paraffin sections was performed by immersion of the slides in 10 mM citrate buffer (10 mM citrate monohydrate in distilled water, pH 6.0) and exposure to microwave irradiation twice for 5 min with a cooling period of 3 min in between the Tusjimoto and Croce, 1986; Pezzella et al., 1990) . Its efficacy has been proven on frozen sections and on paraffin sections (Pezzella et al., 1990 (Pezzella et al., , 1992 (Pezzella et al., , 1993 LeBrun et al., 1992; Leek et al., 1994; Silvestrini et al., 1994) . The sections were then overlaid with biotinylated rabbit antimouse polyclonal antibody (Dako) diluted 1:300. Binding was detected by applying the avidin-biotin-peroxidase complex (Dako). DAB (3-3'-diaminobenzidine tetrahydrochloride) was used as chromogen and Mayer's haematoxylin was used as counterstain. Negative controls were performed by omitting the primary antibody and by substituting the anti-bcl-2 antibody for an unrelated monoclonal antibody of the same isotype IgGI in the same concentration but directed against an unrelated antigen (monoclonal mouse anti-human CD68 antibody, isotype IgGI; Dako). Sections of a follicular lymphoma were used as positive controls (Cleary et al., 1986; Tusjimoto and Croce, 1986) . Bcl-2 cytoplasmic immunoreactivity was quantified by counting at least 1000 tumour cells in different random fields, using a high-power (400 x ) objective. Results were expressed as percentage of tumour cells staining positively for bcl-2. For further statistical analysis two groups of tumours were defined: tumours containaing 10% or less (bcl-2 negative) and tumours containing more than 10% positively staining tumour cells (bcl-2 positive). This cut-off value was chosen taking into account statistical guidelines for prognostic factor studies in oncology (Simon and Altman, 1994 Overall survival curves and disease-free survival curves, starting from the date of surgery, were plotted using the Kaplan and Meier (1958) method and their statistical significance was calculated by use of the log-rank test. Locoregional disease relapse and/or distant metastases were considered end points for disease-free survival. Cox's (1972) proportional hazard regression analysis was used for multivariate analysis and for calculation of the hazard ratios and their confidence intervals.
For all statistical analyses a P-value <0.05 was considered statistically significant.
Results
Tissue distribution of bcl-2 immunoreactivity Sixty-three (25%) tumours were scored as bcl-2 negative and 188 (75%) tumours were scored as bcl-2 positive. In bcl-2-positive cases no relationship was observed between location of bcl-2 immunoreactivity and definite neoplastic areas (tumour centre vs infiltrative margins). In all tumour sections stromal fibroblasts were bcl-2 negative and lymphocytes were bcl-2 positive. Cytoplasmic immunoreactivity for bcl-2 protein was always observed in normal mammary glandular tissue in those sections containing normal breast tissue adjacent to the tumour.
Association with clinicopathological variables
Correlations between bcl-2 immunoreactivity and clinicopathological variables are shown in Table I . No relationship was demonstrated between bcl-2 immunoreactivity and tumour grade, tumour size, nodal status, presence or absence of metastases or menopausal status. A significant positive relationship was found between bcl-2 immunoreactivity and oestrogen receptor status (P<0.001) or progesterone receptor status (P<O.001). overall survival as evaluated by Cox regression analysis is given in In the group of axillary node-negative patients (n = 124) (median follow-up time 84 months, range 24-161 months) univariate analysis revealed no statistical difference in disease-free survival (log-rank test, P = 0.077) or in overall survival (log-rank test, P = 0.139) between bcl-2-negative and bcl-2-positive tumours (Figure 2) In the group of axillary node-positive patients (n = 107)
. Time (months) Figure 2 Kaplan-Meier life table analysis for disease-free survival (log-rank test, P = 0.077) and for overall survival (log-rank test, P = 0.139) in axillary node-negative patients (n = 124). It needs to be emphasised that our survival curves for disease-free survival and overall survival in the different patient groups have been plotted up to 180 months, although the median follow-up period in our study group was 91 months. Owing to the limited number of patients at risk at the end of the curves, disease-free survival rates and overall survival rates beyond 130 months follow-up time should be interpreted with caution (Figures 1-3 ).
Discussion
The bcl-2 proto-oncogene has been demonstrated to be an inhibitor of programmed cell death without promoting cell proliferation (Hockenberry et al., 1990 In the present study we observed a strong positive relationship between bcl-2 immunoreactivity and oestrogen and progesterone receptor status. This is in agreement with previously published data (Chan et al., 1993; Bhargava et al., 1994; Doglioni et al., 1994; Gee et al., 1994; Leek et al., 1994; Nathan et al., 1994; Silvestrini et al., 1994) . These observations support the hypothesis that bcl-2 expression in breast carcinoma may be an oestrogen receptor-regulated phenomenon.
Silvestrini et al. (1994) studied the prognostic value of the bcl-2 oncoprotein on 6 year relapse-free and overall survival in 283 axillary node-negative breast cancer patients. Univariate analysis demonstrated low bcl-2 immunoreactivity to be associated with shortened relapse-free and overall survival. Multivariate analysis including bcl-2 status, tumour size [3H]thymidine labelling index and ER status demonstrated an independent prognostic role for bcl-2 expression. However, no prognostic role for bcl-2 expression on 6 year relapse-free survival and overall survival was retained when p53 expression was included in the multivariate analysis (Silvestrini et al., 1994) . In a series of 174 women with breast cancer treated with radical surgery with or without locoregional radiotherapy and with very long-term follow-up (median 31 years), a significant association was demonstrated 2, 'Adjusted hazards ratio of relapsing or dying (95% confidence intervals). hLikelihood ratio statistic on one degree of freedom.
cReference category. dMean hazard ratio between two adjacent categories. between low bcl-2 expression and shortened overall survival following univariate analysis in axillary node-positive but not in axillary node-negative patients. Following multivariate analysis no independent prognostic role for bcl-2 expression was retained in axillary node-negative or in axillary nodepositive patients (Joensuu et al., 1994) . In the present series we studied the prognostic value of bcl-2 expression on disease-free survival and overall survival in 231 breast cancer patients initially staged as MO. Univariate analysis and multivariate analysis including established prognostic factors in breast carcinoma demonstrated absence of bcl-2 expression to be independently associated with shortened disease-free survival and shortened overall survival in axillary node-positive breast cancer but not in axillary node-negative breast cancer. The observed prognostic role for bcl-2 expression in the complete study population mainly reflects its strong prognostic value in axillary node-positive breast cancer. Our study results in part confirm the results obtained in previous studies but demonstrate an intriguing prognostic role for bcl-2 expression in axillary node-positive breast cancer.
In follicular lymphoma the presence of bcl-2 overexpression as a consequence of the t(14;18) translocation has no prognostic value and appears to be a hallmark for slow tumour progression (Pezzella et al., 1992) . In non-small-cell lung carcinoma the observation of a group of bcl-2-positive tumours with relatively slow disease progression suggests a role for bcl-2 expression as an initial oncogenic effect leading to less aggressive tumour growth as observed in follicular lymphoma (Pezzella et al., 1993) . The observed difference in independent prognostic power for bcl-2 expression between axillary node-negative and axillary node-positive patients in our series is extremely interesting and needs further elucidation. In vitro and in vivo studies have demonstrated a role for the bcl-2 protein in the prevention of apoptosis induced by anti-cancer drugs (Campos et al., 1993; Miyashita and Reed, 1993) . Bcl-2 transfection has been demonstrated to confer resistance to anti-cancer agents by non-conventional drugresistance pathways . A recent study in breast cancer has reported bcl-2 immunostaining to be a better predictor for response to systemic endocrine therapy than oestrogen receptor status in a limited series of patients who only received endocrine therapy following primary surgery (Gee et al., 1994) . In contrast to our findings, Joensuu et al. (1994) could not demonstrate a prognostic role for bcl-2 expression on overall survival in axillary node-positive breast cancer patients primarily treated by radical surgery with or without locoregional radiotherapy and in whom no adjuvant therapy was administered. These data and our study results strongly suggest a role for bcl-2 expression as a predictor for response to chemotherapy or endocrine therapy in breast cancer patients. However, investigating such interactions in our study population is problematic because of the need for subgroup analysis in limited numbers of patients and because of the heterogeneous character of second-line and third-line treatment in those patients developing locoregional disease relapse and/or distant metastases which consists of various combinations of chemotherapy and/or endocrine therapy and/or radiotherapy. Larger patient groups with better standardised curative and palliative treatment protocols are needed to study the role of bcl-2 as a modulator of response to chemotherapy or endocrine therapy in breast cancer.
To what extent bcl-2 expression influences apoptotic cell death rate in solid neoplasms and its final effect on disease progression remains to be resolved. Recently, cDNAs have been cloned for several novel human genes, revealing a family of bcl-2 related proteins. The bax protein has been demonstrated to promote apoptosis by opposing bcl-2's function through heterodimerisation (Oltvai et al., 1993) . Bcl-XL has been shown to inhibit apoptosis, whereas its shorter alternative splice form bcl-xs, promotes apoptosis (Boise et al., 1993) . The MCL1 gene and the Al gene have been demonstrated to have sequence similarity with the bct-2 gene, although their function remains unknown (Kozopas et al., 1993; Lin et al., 1993) . Other non-bcl-2-related proteins playing a role in the regulation of programmed cell death have been isolated (Gagliardini et al., 1993; Nakashima et al., 1993) .
Other important oncogenes and tumour-suppressor genes play a role in the regulation of apoptosis. c-myc, although generally considered as an important element in proliferation control, induces apoptosis in specific conditions Shi et al., 1992) . The action of c-myc as a stimulator of both mitogenesis and apoptosis appears to be dependent on the presence of bcl-2 (Bissonnette et Fanidi et al., 1992) . Wild-type p53 has been demonstrated to be able to induce apoptosis (Yonis-Rouach et al., 1991) . The bcl-2 gene is a transcriptional target for wild-type p53. Wild-type p53 decreases bcl-2 protein levels and increases bax protein levels in vitro and in vivo, explaining the ability of p53 to induce apoptotic cell death (Miyashita et al., 1994a,b) . Furthermore, in breast cancer cell lines mutant p53 induces downregulation of bcl-2 at both mRNA and protein level (Haldar et al., 1994) . The critical role played by p53 in the carcinogenesis of human breast cancer is well documented. About 30-50% of human breast cancers carry a mutant p53 gene and about an additional 30% carry non-functional wildtype p53 sequestered in the cytoplasm of tumour cells (Moll et al., 1992) . The presence of mutated or overexpressed p53 has been associated with poor prognostic markers, such as high histopathological grading, high levels of Ki67 or EGFR and the absence of hormone receptors, as well as with shortened disease-free survival and/or overall survival (Cattoretti et al., 1988; Isola et al., 1992; Poller et al., 1992; Thor et al., 1992; Allred et al., 1993) . The inverse correlation between bcl-2 expression and the presence of immunohistochemically demonstrable mutant p53 observed in breast cancer could reflect down-regulation of bcl-2 by mutant p53 (Doglioni et al., 1994; Joensuu et al., 1994; Leek et al., 1994; Silvestrini et al., 1994) .
We conclude absence of bcl-2 expression to be an independent marker of poor prognosis in axillary node-positive breast cancer. Absence of bcl-2 expression in invasive ductal breast carcinoma possibly reflects down-regulation of the bcl-2 gene by mutant p53. Our results suggest a potentially important role for bcl-2 as a modulator of response to adjuvant therapy in breast cancer.
